Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
4
×
deals
new york top stories
beta-thalassemia
biotech
boston
clinical trials
dna
fda
new york
san francisco blog main
achromatopsia
alnylam pharmaceuticals
amgen
azacitidine
bill cassidy
bluebird bio
cancer
cancer immunotherapy
center for medicare and medicaid services
cholesterol
companion diagnostic
dacogen
daniel o'day
decitabine
epigenetics
epizyme
farydak
flagship pioneering
foundation medicine
foundationone cdx
foundationone heme
fulcrum therapeutics
gene therapy
genentech
What
morning
4
×
medicines
touting
acquire
age
agreed
aims
approach
based
big
bigger
biggest
billion
biotech
bringing
broad
called
cholesterol
clears
closer
come
confidence
deal
debuts
developing
didn’t
drug
drugs
emerging
epigenetic
epigenetics
fda
field
filing
flagship’s
foundation
gain
gave
gene
genentech
Language
unset
Current search:
morning
×
" new york blog main "
×
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine